探究PET体内发生器铈-134作为锕-225治疗诊断匹配对的可行性
本研究在荷瘤小鼠中直接比较了225Ac与134Ce标记的示踪剂,发现两者在体内药代动力学上具有可比性,但134Ce PET定量高度依赖示踪剂内化,因子体134La再分布导致慢内化载体的肿瘤摄取被低估,而这一特性也可用于无创评估225Ac子体的再分布。
要点
- 134Ce/134La与225Ac在体内药代动力学上具有可比性,是潜在的治疗诊断匹配对。
- 134Ce PET定量高度依赖示踪剂内化,慢内化载体的肿瘤摄取会被低估。
- 134Ce子体134La的再分布特性可用于无创评估225Ac子体的再分布。
核心结论
- 使用慢内化载体时,由于134La的体内再分布导致肿瘤摄取被低估,134Ce可能不是225Ac的理想匹配。
- 但这一特性使得能够无创地估计225Ac子体的再分布。
- 未来研究将进一步利用这一独特的PET体内发生器来研究示踪剂内化、受体转运和肿瘤微环境进展。
研究设计与样本
- 采用内化型和慢内化型癌症模型,在体外和体内直接比较225Ac与134Ce标记的示踪剂。
- 将前体PSMA-617和基于macropa的四嗪偶联物(mcp-PEG8-Tz)分别用225Ac或134Ce进行放射性标记。
- 在无胸腺裸鼠中,利用生物分布研究和PET成像,在PC3/PIP前列腺癌小鼠模型中评估放射性标记的PSMA-617示踪剂。
- 在BxPC-3胰腺肿瘤模型中,利用基于反式环辛烯修饰的5B1单克隆抗体的预靶向策略,研究225Ac和134Ce标记的mcp-PEG8-Tz。
主要发现
- 225Ac和134Ce标记示踪剂的体外和体内研究结果相当,证实了该治疗诊断配对匹配的药代动力学。
- 134Ce标记前体的PET成像表明,由于134Ce的PET兼容子体134La的再分布,定量高度依赖示踪剂内化。
- 基于内化载体(如PSMA-617)的放射性示踪剂适合该治疗诊断配对,而慢内化225Ac标记示踪剂不能由134Ce PET成像定量代表。
临床怎么用
- 原文未据此给出推荐。
局限性
- 使用慢内化载体时,134Ce可能不是225Ac的理想匹配,原因是134La的体内再分布导致肿瘤摄取被低估。
- 134Ce/134La在定量PET成像方面存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The radionuclide pair cerium-134/lanthanum-134 (134Ce/134La) was recently proposed as a suitable diagnostic counterpart for the therapeutic alpha-emitter actinium-225 (225Ac). The unique properties of 134Ce offer perspectives for developing innovative in vivo investigations that are not possible with 225Ac. In this work, 225Ac- and 134Ce-labelled tracers were directly compared using internalizing and slow-internalizing cancer models to evaluate their in vivo comparability, progeny meandering, and potential as a matched theranostic pair for clinical translation. Despite being an excellent chemical match, 134Ce/134La has limitations to the setting of quantitative positron emission tomography imaging. METHODS: The precursor PSMA-617 and a macropa-based tetrazine-conjugate (mcp-PEG8-Tz) were radiolabelled with 225Ac or 134Ce and compared in vitro and in vivo using standard (radio)chemical methods. Employing biodistribution studies and positron emission tomography (PET) imaging in athymic nude mice, the radiolabelled PSMA-617 tracers were evaluated in a PC3/PIP (PC3 engineered to express a high level of prostate-specific membrane antigen) prostate cancer mouse model. The 225Ac and 134Ce-labelled mcp-PEG8-Tz were investigated in a BxPC-3 pancreatic tumour model harnessing the pretargeting strategy based on a trans-cyclooctene-modified 5B1 monoclonal antibody. RESULTS: In vitro and in vivo studies with both 225Ac and 134Ce-labelled tracers led to comparable results, confirming the matching pharmacokinetics of this theranostic pair. However, PET imaging of the 134Ce-labelled precursors indicated that quantification is highly dependent on tracer internalization due to the redistribution of 134Ce's PET-compatible daughter 134La. Consequently, radiotracers based on internalizing vectors like PSMA-617 are suited for this theranostic pair, while slow-internalizing 225Ac-labelled tracers are not quantitatively represented by 134Ce PET imaging. CONCLUSION: When employing slow-internalizing vectors, 134Ce might not be an ideal match for 225Ac due to the underestimation of tumour uptake caused by the in vivo redistribution of 134La. However, this same characteristic makes it possible to estimate the redistribution of 225Ac's progeny noninvasively. In future studies, this unique PET in vivo generator will further be harnessed to study tracer internalization, trafficking of receptors, and the progression of the tumour microenvironment.
引用
- Bauer D, De Gregorio R, Pratt EC, et al. Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac. Eur J Nucl Med Mol Imaging. 2024. PMID: 38940841. doi:10.1007/s00259-024-06811-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。